VRTX
VERTEX PHARMACEUTICALS INC / MA
NASDAQ · Healthcare · Biotechnology · US
$549.04
+3.44%Year over year
Reported trailing growth
- Revenue
- +10.8%
- EBITDA
- +6.6%
- EBIT
- +10.1%
- EPS
- +9.3%
- Free cash flow
- -4.0%
- Operating cash flow
- -0.6%
Forward estimates
Based on analyst estimates
- Revenue
- +10.1%
- EBITDA
- +53.4%
- EPS
- +21.6%
Three-year CAGR
- Revenue
- +10.6%
- EBITDA
- +3.1%
- EBIT
- +3.4%
- Net income
- +6.0%
- EPS
- +6.0%
- Free cash flow
- -6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026